The National Institute for Health and Care Excellence

NICE recommends Enhertu for people with HER2-low advanced breast cancer

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.
The National Institute for Health and Care Excellence

Draft guidance aims to improve identification of OCD and body dysmorphic disorder

People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment under draft NICE guidance published today.
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment HTG694 26 September 2023 7 September 2026 Guided self-help digital cognitive ...
National Institute for Health and Care Excellence

Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years

Evidence-based recommendations on mirdametinib (Ezmekly) for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years ...
National Institute for Health and Care Excellence

Appendix F: Methodology checklist: the QUADAS-2 tool for studies of diagnostic test accuracy

The following checklists are taken directly from the 'QUADAS-2' publication (Whiting PF Rutjes AWS, Westwood ME et al. and the QUADAS-2 group [2011] QUADAS-2: a revised tool for the quality assessment ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community

This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...
The National Institute for Health and Care Excellence

How to reveal your market access blind spots

Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Quality statement 4: Duration of antibiotic treatment for urinary tract infection

When a decision is made to prescribe antibiotics, the shortest course that is likely to be effective should be prescribed to reduce the risk of antimicrobial resistance and adverse effects. Short ...
National Institute for Health and Care Excellence

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.